Opinion|Videos|October 4, 2024
Insights on REMS Programs and Strategies for Effective Patient Care
The panel provides an overview of REMS programs for bispecific therapies in multiple myeloma and discusses how institutions can educate healthcare professionals outside of oncology.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
2
Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis
3
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
4
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
5